$0.03
0.00% yesterday
Nasdaq, Feb 04, 03:30 pm CET
ISIN
US0076242082
Symbol
ADXS
Sector
Industry

Advaxis, Inc. Stock price

$0.03
+0.00 5.93% 1M
+0.01 43.00% 6M
+0.00 5.93% YTD
-0.56 95.15% 1Y
-10.88 99.74% 3Y
-73.52 99.96% 5Y
-9,275.97 100.00% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.00 0.00%
ISIN
US0076242082
Symbol
ADXS
Sector
Industry

Key metrics

Market capitalization $1.22m
Enterprise Value $-4.43m
EV/Sales (TTM) EV/Sales -443.00
P/S ratio (TTM) P/S ratio 122.00
Short interest 1.35%

Is Advaxis, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Advaxis, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Advaxis, Inc.:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Advaxis, Inc.:

Hold
100%

Financial data from Advaxis, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Annually
Oct '22
+/-
%
0.25 0.25
92% 92%
100%
- Direct Costs 0.31 0.31
-
124%
-0.06 -0.06
-
-24%
- Selling and Administrative Expenses 8.10 8.10
9% 9%
3,240%
- Research and Development Expense 7.61 7.61
21% 21%
3,044%
-16 -16
3% 3%
-6,312%
- Depreciation and Amortization 0.31 0.31
69% 69%
124%
EBIT (Operating Income) EBIT -16 -16
7% 7%
-6,436%
Net Profit -14 -14
20% 20%
-5,744%

In millions USD.

Don't miss a Thing! We will send you all news about Advaxis, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Advaxis, Inc. Stock News

Neutral
Business Wire
7 days ago
NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced it has entered into an asset purchase agreement to acquire the listeria monocytogenes-based immuno-oncology programs and related intellectual property (IP) assets from Ayala Pharmaceuticals (OTC: ADXS). ...
Neutral
Business Wire
7 days ago
NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced it has entered into an asset purchase agreement to acquire the listeria monocytogenes-based immuno-oncology programs and related intellectual property (IP) assets from Ayala Pharmaceuticals (OTC: ADXS). ...

Company Profile

Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. It has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.

Head office United States
CEO Ken Berlin
Founded 2017
Website www.ayalapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today